THESEUS PHARMACEUTICALS, INC. Financing Cash Flow
THESEUS PHARMACEUTICALS, INC. reported Financing Cash Flow of $49.63 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2023-11-17
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2023-09-30 was $0.00.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2023-06-30 was $142.00K, a 102.86% increase year-over-year.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2023-03-31 was $49.49M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2022-12-31 was $112.00K, a 99.93% decline year-over-year.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $182.00K, a 99.93% decline from fiscal 2021.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2021 was $263.78M, a 2099.61% increase from fiscal 2020.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2020 was $11.99M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $142.00K derived: sum of 2 quarters · filed 2023-11-17 | $49.63M 10-Q · filed 2023-11-17 | $49.74M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $49.63M 10-Q · filed 2023-08-10 | $49.74M derived: sum of 3 quarters · filed 2023-08-10 | $49.74M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | $49.49M 10-Q · filed 2023-05-11 | $49.60M derived: sum of 2 quarters · filed 2023-05-11 | $49.60M derived: sum of 3 quarters · filed 2023-11-17 | $49.67M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $112.00K derived: sum of 2 quarters · filed 2023-11-17 | $182.00K derived: sum of 3 quarters · filed 2023-11-17 | $182.00K 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $70.00K derived: sum of 2 quarters · filed 2023-11-17 | $70.00K 10-Q · filed 2023-11-17 | $164.24M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $70.00K 10-Q · filed 2023-08-10 | $164.24M derived: sum of 3 quarters · filed 2023-08-10 | $162.76M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $164.17M derived: sum of 2 quarters · filed 2023-05-11 | $162.69M derived: sum of 3 quarters · filed 2023-05-11 | $163.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $164.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $162.69M derived: sum of 2 quarters · filed 2023-03-09 | $163.88M derived: sum of 3 quarters · filed 2023-03-09 | $263.78M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$288.00K derived: sum of 2 quarters · filed 2022-11-03 | $99.60M 10-Q · filed 2022-11-03 | $103.60M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $101.09M 10-Q · filed 2022-08-11 | $105.08M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $99.89M 10-Q · filed 2022-05-12 | $103.89M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $11.99M 10-K · filed 2022-03-10 | ||
| 2020-09-30 | $7.99M 10-Q · filed 2021-11-15 |